NCT Number: NCT00109330
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
Looking for future studies?
Notify MeKey information
Conditions
Age range
10 year–18 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
GSK Investigational Site, Mesa, Arizona, United States
About this study
A combined Tdap (Tetanus, Diphteria, Acellular Pertussis) Vaccine Used as a Booster compared to Licensed Td (Tetanus and Diphteria) vaccine
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP).
Exclusion criteria
- Use of any other investigational drug or vaccine 30 days preceding study vaccination.
- Chronic administration of immunosuppressants.
- Administration of pre-school DTP vaccine within previous 5 years.
- Administration of Td booster within previous 10 years.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
GlaxoSmithKline
Industry
Registry information
Official study title
A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)
Important dates
- Study start
- 2002
- Primary completion
- 2004
- Study completion
- 2004
- First posted
- Apr 27, 2005
- Registry last updated
- Sep 9, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.
NCT02569879
Acellular Pertussis, Actinomycetales Infections
Bogotá, Colombia
View Trial DetailsPost-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea
NCT01568060
Acellular Pertussis, Actinomycetales Infections
Seoul, South Korea
View Trial DetailsEvaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
NCT02853929
Acellular Pertussis, Actinomycetales Infections
Carlton, Victoria, Australia
View Trial DetailsUS-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
NCT00282295
Acellular Pertussis, Actinomycetales Infections
Chandler, Arizona, United States
View Trial Details